Funding news
Metrion Biosciences logo

Breaking News: Metrion Biosciences Secures $2.25 Million in Funding for Cutting-Edge Drug Discovery Services

Recently funded · £2.3MBiotechnology

Get the full Metrion Biosciences company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Metrion Biosciences, a leading preclinical drug discovery contract research organization (CRO) specializing in ion channel screening, cardiac safety assessments, and neuroscience assays, has successfully raised £2,250,000 in funding. This significant investment underscores the industry’s confidence in Metrion's innovative approach to drug discovery and its commitment to advancing safety and efficacy profiles of emerging therapeutics. The funds will be strategically utilized to enhance and expand Metrion's cutting-edge in vitro screening services, which includes GLP hERG testing, the CiPA panel of human cardiac ion channels, and neurotoxicology evaluations. By scaling operations and integrating new technologies, Metrion aims to further optimize their service offerings and solidify their position as a trusted partner for pharmaceutical and biotechnology companies navigating the complexities of preclinical drug development. With a team that collectively brings over 250 years of expertise in managing ion channel research programs, Metrion prides itself on delivering flexible, cost-effective solutions tailored to meet client needs. This funding infusion will not only bolster Metrion’s capabilities but also enhance its role in ensuring that drugs entering clinical trials are both safe and effective, ultimately contributing to better healthcare outcomes. As the company embarks on this new chapter of growth, stakeholders can look forward to innovative advancements in drug discovery that prioritize patient safety and scientific excellence.

Other recently funded companies

View all